After tackling vaccination against seven diseases, the Indian government has set its sights on bio-medical research involving children, reports The Pharma Letter’s India correspondent.
The Indian Council of Medical Research has drafted new guidelines on clinical trials with children, stating that the child’s approval would be compulsory in order to take part in any clinical trial.
A spate of fatalities among subjects of clinical trials in India, which made international headlines, and the death of 49 children in six clinical trials conducted at India's premier institute, the All India Institute of Medical Sciences (AIIMS) several years ago, proved to be the proverbial last straw and instrumental in moving the Indian government to shake up its rules on clinical trials involving children.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze